login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SYNDAX PHARMACEUTICALS INC (SNDX) Stock News
USA
-
Nasdaq
- NASDAQ:SNDX -
US87164F1057
-
Common Stock
18.57
USD
-0.55 (-2.88%)
Last: 12/2/2025, 2:22:35 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNDX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
a day ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
25 days ago - By: Zacks Investment Research
- Mentions:
PBYI
ANIP
ARQT
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
a month ago - By: Zacks Investment Research
- Mentions:
ANIP
ACAD
ARQT
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
a month ago - By: Zacks Investment Research
- Mentions:
TEVA
ANIP
ARQT
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
a month ago - By: Benzinga
Syndax Pharmaceuticals's Earnings Outlook
a month ago - By: Benzinga
Why Is Syndax Stock Down Today?
a month ago - By: Stocktwits
- Mentions:
LABU
VHT
SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
a month ago - By: Zacks Investment Research
- Mentions:
STRO
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in November Investor Conferences
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
a month ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 months ago - By: Zacks Investment Research
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade
3 months ago - By: Zacks Investment Research
- Mentions:
A
PAHC
ASTH
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in September Investor Conferences
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in September Investor Conferences
4 months ago - By: Zacks Investment Research
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
4 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Please enable JavaScript to continue using this application.